These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. COVID-19: a conundrum to decipher. Deshmukh V; Tripathi SC; Pandey A; Deshmukh V; Vykoukal J; Patil A; Sontakke B Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5830-5841. PubMed ID: 32495923 [TBL] [Abstract][Full Text] [Related]
4. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Guo YR; Cao QD; Hong ZS; Tan YY; Chen SD; Jin HJ; Tan KS; Wang DY; Yan Y Mil Med Res; 2020 Mar; 7(1):11. PubMed ID: 32169119 [TBL] [Abstract][Full Text] [Related]
6. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a newly emerged pathogen: an overview. Rathore JS; Ghosh C Pathog Dis; 2020 Aug; 78(6):. PubMed ID: 32840560 [TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics of two human-to-human transmitted coronaviruses: Corona Virus Disease 2019 vs. Middle East Respiratory Syndrome Coronavirus. Xu P; Sun GD; Li ZZ Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5797-5809. PubMed ID: 32495918 [TBL] [Abstract][Full Text] [Related]
8. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents. Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711 [TBL] [Abstract][Full Text] [Related]
9. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. Sharma A; Tiwari S; Deb MK; Marty JL Int J Antimicrob Agents; 2020 Aug; 56(2):106054. PubMed ID: 32534188 [TBL] [Abstract][Full Text] [Related]
10. A global treatments for coronaviruses including COVID-19. Yousefi B; Valizadeh S; Ghaffari H; Vahedi A; Karbalaei M; Eslami M J Cell Physiol; 2020 Dec; 235(12):9133-9142. PubMed ID: 32394467 [TBL] [Abstract][Full Text] [Related]
11. COVID-19/SARS-CoV-2 Infection: Lysosomes and Lysosomotropism Implicate New Treatment Strategies and Personal Risks. Blaess M; Kaiser L; Sauer M; Csuk R; Deigner HP Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32668803 [TBL] [Abstract][Full Text] [Related]
12. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. Liu J; Zheng X; Tong Q; Li W; Wang B; Sutter K; Trilling M; Lu M; Dittmer U; Yang D J Med Virol; 2020 May; 92(5):491-494. PubMed ID: 32056249 [TBL] [Abstract][Full Text] [Related]
13. From SARS and MERS CoVs to SARS-CoV-2: Moving toward more biased codon usage in viral structural and nonstructural genes. Kandeel M; Ibrahim A; Fayez M; Al-Nazawi M J Med Virol; 2020 Jun; 92(6):660-666. PubMed ID: 32159237 [TBL] [Abstract][Full Text] [Related]
14. Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity. Schijns V; Lavelle EC Eur J Immunol; 2020 Jul; 50(7):932-938. PubMed ID: 32438473 [TBL] [Abstract][Full Text] [Related]
15. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Rockx B; Kuiken T; Herfst S; Bestebroer T; Lamers MM; Oude Munnink BB; de Meulder D; van Amerongen G; van den Brand J; Okba NMA; Schipper D; van Run P; Leijten L; Sikkema R; Verschoor E; Verstrepen B; Bogers W; Langermans J; Drosten C; Fentener van Vlissingen M; Fouchier R; de Swart R; Koopmans M; Haagmans BL Science; 2020 May; 368(6494):1012-1015. PubMed ID: 32303590 [TBL] [Abstract][Full Text] [Related]
16. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status. Abd El-Aziz TM; Stockand JD Infect Genet Evol; 2020 Sep; 83():104327. PubMed ID: 32320825 [TBL] [Abstract][Full Text] [Related]
17. The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development. Alturki SO; Alturki SO; Connors J; Cusimano G; Kutzler MA; Izmirly AM; Haddad EK Front Immunol; 2020; 11():1880. PubMed ID: 32973779 [TBL] [Abstract][Full Text] [Related]
18. Emergence of a Novel Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2: Biology and Therapeutic Options. Khan S; Siddique R; Shereen MA; Ali A; Liu J; Bai Q; Bashir N; Xue M J Clin Microbiol; 2020 Apr; 58(5):. PubMed ID: 32161092 [TBL] [Abstract][Full Text] [Related]
19. Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection. Liang Y; Wang ML; Chien CS; Yarmishyn AA; Yang YP; Lai WY; Luo YH; Lin YT; Chen YJ; Chang PC; Chiou SH Front Immunol; 2020; 11():1022. PubMed ID: 32574260 [TBL] [Abstract][Full Text] [Related]
20. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. Li YC; Bai WZ; Hashikawa T J Med Virol; 2020 Jun; 92(6):552-555. PubMed ID: 32104915 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]